{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:25:18Z","timestamp":1790483118986,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11010-020-03891-8","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:11:58Z","timestamp":1598415118000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recent updates on novel therapeutic targets of cardiovascular diseases"],"prefix":"10.1007","volume":"476","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-3223","authenticated-orcid":false,"given":"Muhammad","family":"Afzal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"3891_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1573403X14666180222102312","volume":"14","author":"FZ Sonja","year":"2018","unstructured":"Sonja FZ, Iskra AN (2018) Management of measurable variable cardiovascular disease' risk factors. Curr Cardiol Rev 14:153\u2013163","journal-title":"Curr Cardiol Rev"},{"key":"3891_CR2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.15836\/ccar.2013.373","volume":"8","author":"V Kralj","year":"2013","unstructured":"Kralj V, Brkic BI (2013) Morbidity and mortality from cardiovascular diseases. Cardiol Croat 8:373\u2013378","journal-title":"Cardiol Croat"},{"key":"3891_CR3","first-page":"38","volume":"25","author":"DF Gagan","year":"2019","unstructured":"Gagan DF, Manasa KN (2019) Brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des 25:38","journal-title":"Curr Pharm Des"},{"issue":"14","key":"3891_CR4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D (2011) ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769\u20131818","journal-title":"Eur Heart J"},{"key":"3891_CR5","unstructured":"Olvera LE, Ballard BD, Jan A (2020) Cardiovascular disease. In: Stat Pearls. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535419\/. Accessed 29 May 2020"},{"issue":"12","key":"3891_CR6","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW et al (2018) American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: a Report From the American Heart Association. Circulation 137(12):e67\u2013e492","journal-title":"Circulation"},{"issue":"9438","key":"3891_CR7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937\u2013952","journal-title":"Lancet"},{"issue":"20","key":"3891_CR8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","volume":"292","author":"CS Fox","year":"2004","unstructured":"Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB, Wilson PW, Savage PJ (2004) Trends in cardiovascular complications of diabetes. JAMA 292(20):2495\u20132499","journal-title":"JAMA"},{"issue":"19","key":"3891_CR9","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1161\/CIR.0000000000000570","volume":"137","author":"SB Dunbar","year":"2018","unstructured":"Dunbar SB, Khavjou OA, Bakas T, Hunt G, Kirch RA, Leib AR, Morrison RS, Poehler DC, Roger VL, Whitsel LP (2018) American Heart Association: projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: a policy statement from the American Heart Association. Circulation 137(19):e558\u2013e577","journal-title":"Circulation"},{"issue":"7347","key":"3891_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317\u2013325","journal-title":"Nature"},{"issue":"6","key":"3891_CR11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/hrt.60.6.459","volume":"60","author":"MJ Davies","year":"1988","unstructured":"Davies MJ, Woolf N, Rowles PM, Pepper J (1988) Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 60(6):459\u2013464","journal-title":"Br Heart J"},{"issue":"7","key":"3891_CR12","first-page":"e46","volume":"121","author":"D Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M et al (2010) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20132010 update: a report from the American Heart Association. Circulation 121(7):e46\u2013e215","journal-title":"Circulation"},{"key":"3891_CR13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/HYPERTENSIONAHA.114.03116","volume":"64","author":"A Qadeer","year":"2014","unstructured":"Qadeer A, Alison MT, John G, Richard A, William RS et al (2014) The ATP-sensitive potassium channel subunit, Kir6.1, in vascular smooth muscle plays a major role in blood pressure control. Hypertension 64:523\u2013529","journal-title":"Hypertension"},{"issue":"3","key":"3891_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0b013e3181e23e2b","volume":"56","author":"YP Zhi","year":"2010","unstructured":"Zhi YP, Jing HH, Wen YC, Chao LL, Yan FZ, Hai W (2010) Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol 56(3):215\u2013228","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3891_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FJC.0b013e3181eb4e75","volume":"56","author":"FB Priviero","year":"2010","unstructured":"Priviero FB, Webb RC (2010) Heme- dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol 56(3):229\u2013233","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3891_CR16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e3181f0d63f","volume":"56","author":"WB George","year":"2010","unstructured":"George WB (2010) Novel drugs targeting hypertension revisited. J Cardiovasc Pharmacol 56(3):213\u2013214","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"3891_CR17","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1096\/fj.10-160119","volume":"24","author":"CR Lee","year":"2010","unstructured":"Lee CR, Imig JD, Edin ML, Foley J et al (2010) Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 24(10):3770\u20133781","journal-title":"FASEB J"},{"issue":"4","key":"3891_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-7133.2008.08430.x","volume":"14","author":"TR Harris","year":"2008","unstructured":"Harris TR, Li N, Chiamvimonvat N, Hammock BD (2008) The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy. Congest Heart Fail 14(4):219\u2013224","journal-title":"Congest Heart Fail"},{"issue":"8","key":"3891_CR19","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/HJH.0b013e328349062f","volume":"29","author":"Z Honetschl\u00e4gerov\u00e1","year":"2011","unstructured":"Honetschl\u00e4gerov\u00e1 Z, Sporkov\u00e1 A, Kopkan L et al (2011) Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 29(8):1590\u20131601. https:\/\/doi.org\/10.1097\/HJH.0b013e328349062f","journal-title":"J Hypertens"},{"issue":"10","key":"3891_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/CS20090459","volume":"118","author":"CV Cert\u00edkov\u00e1","year":"2010","unstructured":"Cert\u00edkov\u00e1 CV, Walkowska A, Kompanowska JE, Sadowski J (2010) Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond) 118(10):617\u2013632","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"3891_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ancard.2018.04.018","volume":"67","author":"M Hamzaoui","year":"2018","unstructured":"Hamzaoui M, Guerrot D, Djerada Z, Duflot T, Richard V, Bellien J (2018) Cardiovascular consequences of chronic kidney disease, impact of modulation of epoxyeicosatrienoic acids. Ann Cardiol Angeiol (Paris) 67(3):141\u2013148. https:\/\/doi.org\/10.1016\/j.ancard.2018.04.018","journal-title":"Ann Cardiol Angeiol (Paris)"},{"issue":"5","key":"3891_CR22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","volume":"37","author":"J Olearczyk","year":"2014","unstructured":"Olearczyk J, Gao S, Eybye M, Yendluri S et al (2014) Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res 37(5):405\u2013412","journal-title":"Hypertens Res"},{"key":"3891_CR23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","volume":"26","author":"UM Steckelings","year":"2005","unstructured":"Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor\u2014a matter of love and hate. Peptides 26:1401\u20131409","journal-title":"Peptides"},{"key":"3891_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9218531","author":"T Azegami","year":"2019","unstructured":"Azegami T, Itoh H (2019) Vaccine development against the renin-angiotensin system for the treatment of hypertension. Int J Hypertens. https:\/\/doi.org\/10.1155\/2019\/9218531","journal-title":"Int J Hypertens"},{"issue":"1","key":"3891_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10641963.2014.897718","volume":"37","author":"F Halleck","year":"2015","unstructured":"Halleck F, Schr\u00f6der K, Holleck-Weithmann S, Kossmehl P, Kreutz R, Rothermund L (2015) Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade. Clin Exp Hypertens 37(1):26\u201332. https:\/\/doi.org\/10.3109\/10641963.2014.897718","journal-title":"Clin Exp Hypertens"},{"key":"3891_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/2048004014522440","author":"H Milan","year":"2014","unstructured":"Milan H, Ferro A (2014) Aldosterone synthase inhibitors in hypertension: current status and future possibilities. J R Soc Med Cardiovasc Dis. https:\/\/doi.org\/10.1177\/2048004014522440","journal-title":"J R Soc Med Cardiovasc Dis"},{"issue":"6","key":"3891_CR27","doi-asserted-by":"publisher","first-page":"9159","DOI":"10.1002\/jcb.28191","volume":"120","author":"H Akbari","year":"2019","unstructured":"Akbari H, Asadikaram G, Vakili S, Masoumi M (2019) Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: the role of gene polymorphism. J Cell Biochem 120(6):9159\u20139171. https:\/\/doi.org\/10.1002\/jcb.28191","journal-title":"J Cell Biochem"},{"issue":"1","key":"3891_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm9010016","volume":"9","author":"H Martynowicz","year":"2019","unstructured":"Martynowicz H, Wieckiewicz M, Poreba R et al (2019) The relationship between sleep bruxism intensity and renalase concentration-an enzyme involved in hypertension development. J Clin Med 9(1):16. https:\/\/doi.org\/10.3390\/jcm9010016","journal-title":"J Clin Med"},{"issue":"9","key":"3891_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE et al (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373(9):834\u2013844. https:\/\/doi.org\/10.1056\/NEJMoa1413687","journal-title":"N Engl J Med"},{"key":"3891_CR30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.hco.0000245733.09594.66","volume":"21","author":"BK Sastry","year":"2006","unstructured":"Sastry BK (2006) Pharmacologic treatment for pulmonary arterial hypertension. Curr Opin Cardiol 21:561\u2013568","journal-title":"Curr Opin Cardiol"},{"key":"3891_CR31","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393\u20131401. https:\/\/doi.org\/10.1056\/NEJMoa1402670","journal-title":"N Engl J Med"},{"issue":"8","key":"3891_CR32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14(8):803\u2013869","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3891_CR33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lars HL (2017) Global public health burden of heart failure. Card Fail Rev 3(1):7\u201311","journal-title":"Card Fail Rev"},{"key":"3891_CR34","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS et al (2016) American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation 133:e38\u2013e360. https:\/\/doi.org\/10.1161\/CIR.0000000000000350","journal-title":"Circulation"},{"key":"3891_CR35","first-page":"887","volume":"12","author":"OB Kwadwo","year":"2016","unstructured":"Kwadwo OB, Isaac KO, Kwame OB, Daniel DR, Amudha K (2016) Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag 12:887\u2013906","journal-title":"Ther Clin Risk Manag"},{"issue":"7181","key":"3891_CR36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nature06798","volume":"451","author":"JO Mudd","year":"2008","unstructured":"Mudd JO, Kass DA (2008) Tackling heart failure in the twenty-first century. Nature 451(7181):919\u2013928","journal-title":"Nature"},{"issue":"5","key":"3891_CR37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/CIRCRESAHA.111.252981","volume":"110","author":"L Tilemann","year":"2012","unstructured":"Tilemann L, Ishikawa K, Weber T, Hajjar RJ (2012) Gene therapy for heart failure. Circ Res 110(5):777\u2013793","journal-title":"Circ Res"},{"issue":"10","key":"3891_CR38","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1113\/JP272781","volume":"595","author":"G Santulli","year":"2017","unstructured":"Santulli G, Nakashima R, Yuan Q, Marks AR (2017) Intracellular calcium release channels: an update. J Physiol 595(10):3041\u20133051. https:\/\/doi.org\/10.1113\/JP272781","journal-title":"J Physiol"},{"issue":"12","key":"3891_CR39","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1172\/JCI37649","volume":"120","author":"J Shan","year":"2010","unstructured":"Shan J, Betzenhauser MJ, Kushnir A et al (2010) Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. J Clin Invest 120(12):4375\u20134387","journal-title":"J Clin Invest"},{"issue":"3","key":"3891_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jchf.2018.09.001","volume":"7","author":"A Banke","year":"2019","unstructured":"Banke A, Fosb\u00f8l EL, Ewertz M et al (2019) Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 7(3):217\u2013224. https:\/\/doi.org\/10.1016\/j.jchf.2018.09.001","journal-title":"JACC Heart Fail"},{"issue":"11","key":"3891_CR41","doi-asserted-by":"publisher","first-page":"e0166710","DOI":"10.1371\/journal.pone.0166710","volume":"11","author":"T Yasui","year":"2016","unstructured":"Yasui T, Masaki T, Arita Y et al (2016) Molecular characterization of striated muscle-specific Gab1 isoform as a critical signal transducer for neuregulin-1\/ErbB signaling in cardiomyocytes. PLoS ONE 11(11):e0166710. https:\/\/doi.org\/10.1371\/journal.pone.0166710","journal-title":"PLoS ONE"},{"issue":"3","key":"3891_CR42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1470320308097416","volume":"9","author":"H Krum","year":"2008","unstructured":"Krum H (2008) Role of renin in heart failure and therapeutic potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 9(3):177\u2013180","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"3891_CR43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNH.0b013e328040bfab","volume":"16","author":"G Nguyen","year":"2007","unstructured":"Nguyen G (2007) The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens 16(2):129\u2013133","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"3891_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0104-4230(12)70170-7","volume":"58","author":"WM Bernardo","year":"2012","unstructured":"Bernardo WM, Moreira FT (2012) Does nesiritide reduce mortality and readmission in decompensated heart failure? Rev Assoc M\u00e9d Bras 58(2):133\u2013134","journal-title":"Rev Assoc M\u00e9d Bras"},{"issue":"1","key":"3891_CR45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365(1):32\u201343","journal-title":"N Engl J Med"},{"key":"3891_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.peptides.2018.10.002","volume":"111","author":"T Miyauchi","year":"2019","unstructured":"Miyauchi T, Sakai S (2019) Endothelin and the heart in health and diseases. Peptides 111:77\u201388. https:\/\/doi.org\/10.1016\/j.peptides.2018.10.002","journal-title":"Peptides"},{"issue":"6","key":"3891_CR47","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","volume":"74","author":"M Barton","year":"2019","unstructured":"Barton M, Yanagisawa M (2019) Endothelin: 30 years from discovery to therapy. Hypertension 74(6):1232\u20131265","journal-title":"Hypertension"},{"issue":"6","key":"3891_CR48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","volume":"2","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Miller R, Solomon SD (2014) Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2(6):663\u2013670. https:\/\/doi.org\/10.1016\/j.jchf.2014.09.001","journal-title":"JACC Heart Fail"},{"issue":"4","key":"3891_CR49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","volume":"57","author":"LG Hegde","year":"2011","unstructured":"Hegde LG, Yu C, Renner T et al (2011) Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 57(4):495\u2013504","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3891_CR50","first-page":"349","volume":"11","author":"RA Rose","year":"2010","unstructured":"Rose RA (2010) CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Curr Opin Investig Drugs 11(3):349\u2013356","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"3891_CR51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MJT.0b013e3181f890ad","volume":"18","author":"T Mondritzki","year":"2011","unstructured":"Mondritzki T, Kolkhof P, Sabbah HN et al (2011) Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2\/V1a receptor blockade in a preclinical heart failure model. Am J Ther 18(1):31\u201337","journal-title":"Am J Ther"},{"issue":"1","key":"3891_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejheart.2007.10.012","volume":"10","author":"C Torp-Pedersen","year":"2008","unstructured":"Torp-Pedersen C, Kober L, Carlsen JE et al (2008) A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 10(1):89\u201395","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"3891_CR53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.hlc.2016.08.003","volume":"26","author":"AM Selim","year":"2017","unstructured":"Selim AM, Sarswat N, Kelesidis I, Iqbal M, Chandra R, Zolty R (2017) Plasma serotonin in heart failure: possible marker and potential treatment target. Heart Lung Circ 26(5):442\u2013449. https:\/\/doi.org\/10.1016\/j.hlc.2016.08.003","journal-title":"Heart Lung Circ"},{"issue":"16","key":"3891_CR54","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","volume":"53","author":"MJ Meyers","year":"2010","unstructured":"Meyers MJ, Arhancet GB, Hockerman SL et al (2010) Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic Acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 53(16):5979\u20136002","journal-title":"J Med Chem"},{"issue":"31","key":"3891_CR55","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463","journal-title":"Eur Heart J"},{"key":"3891_CR56","first-page":"303","volume":"9","author":"KO Bonsu","year":"2013","unstructured":"Bonsu KO, Kadirvelu A, Reidpath DD (2013) Statins in heart failure: do we need another trial? Vasc Health Risk Manag 9:303\u2013319","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"3891_CR57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00395-013-0356-y","volume":"108","author":"U Hofmann","year":"2013","unstructured":"Hofmann U, Frantz S (2013) How can we cure a heart \u201cin flame\u201d? A translational view on inflammation in heart failure. Basic Res Cardiol 108(4):356","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"3891_CR58","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/MJT.0b013e3181d70453","volume":"18","author":"C Palaniswamy","year":"2011","unstructured":"Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D (2011) Metabolic modulation: a new therapeutic target in treatment of heart failure. Am J Ther 18(6):e197\u2013e201","journal-title":"Am J Ther"},{"issue":"6","key":"3891_CR59","first-page":"421","volume":"46","author":"SV Lakshmi","year":"2009","unstructured":"Lakshmi SV, Padmaja G, Kuppusamy P, Kutala VK (2009) Oxidative stress in cardiovascular disease. Indian J Biochem Biophys 46(6):421\u2013440","journal-title":"Indian J Biochem Biophys"},{"issue":"4","key":"3891_CR60","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1253\/circj.CJ-17-1049","volume":"82","author":"S Tanno","year":"2018","unstructured":"Tanno S, Yamamoto K, Kurata Y et al (2018) Protective effects of topiroxostat on an ischemia-reperfusion model of rat hearts. Circ J 82(4):1101\u20131111. https:\/\/doi.org\/10.1253\/circj.CJ-17-1049","journal-title":"Circ J"},{"key":"3891_CR61","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","volume":"296","author":"AS Go","year":"2006","unstructured":"Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296:2105\u20132111","journal-title":"JAMA"},{"key":"3891_CR62","unstructured":"Kazmi I, Afzal A, Anwar F (2014) Extraction and isolation of novel cardioprotective ursolic acid stearoyl glucoside from the leaves of Lantana camara Linn. Official Journals of the Patent Office, Application No.273\/DEL\/2013 A, Isssue no. 34\/2014, p 32197"},{"key":"3891_CR63","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","volume":"17","author":"IF Al-Harbi","year":"2017","unstructured":"Al-Harbi IF, NO, et al (2017) Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress. Cardiovasc Toxicol 17:58\u201366. https:\/\/doi.org\/10.1007\/s12012-015-9356-5","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"3891_CR64","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/s20030765","volume":"20","author":"R Czabanski","year":"2020","unstructured":"Czabanski R, Horoba K, Wrobel J, Matonia A, Martinek R, Kupka T et al (2020) Detection of atrial fibrillation episodes in long-term heart rhythm signals using a support vector machine. Sensors (Basel) 20(3):765","journal-title":"Sensors (Basel)"},{"issue":"1","key":"3891_CR65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-019-6450-2","volume":"20","author":"Y Yu","year":"2020","unstructured":"Yu Y, Wang Q, Sun J, Zhao J, Chen S, Li Y (2020) Fast growing angiosarcoma of the right atrium after radiofrequency catheter ablation: a missed diagnosis or misdiagnosis case report. BMC Cancer 20(1):13","journal-title":"BMC Cancer"},{"key":"3891_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-2517-9_1","volume":"1177","author":"C Shao","year":"2020","unstructured":"Shao C, Wang J, Tian J, Tang YD (2020) Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol 1177:1\u201336","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"3891_CR67","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10557-019-06910-z","volume":"33","author":"YH Chan","year":"2019","unstructured":"Chan YH, Lee HF, Chao TF, Wu CT, Chang SH, Yeh YH, See LC, Kuo CT, Chu PH, Wang CL, Lip GYH (2019) Real-world comparisons of direct oral anticoagulants for stroke prevention in Asian patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Drugs Ther 33(6):701\u2013710","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"3891_CR68","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.3390\/diagnostics10070435","volume":"10","author":"M St\u0119pie\u0144-Wojno","year":"2020","unstructured":"St\u0119pie\u0144-Wojno M, Poni\u0144ska J, Biernacka EK, Foss-Nieradko B, Chwyczko T, Syska P, P\u0142oski R, Bili\u0144ska ZT (2020) A recurrent exertional syncope and sudden cardiac arrest in a young athlete with known pathogenic p.Arg420Gln variant in the RYR2 gene. Diagnostics (Basel) 10(7):E435","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"3891_CR69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/europace\/eux025","volume":"20","author":"HA Van","year":"2018","unstructured":"Van HA, Nasrallah H, Lau DH, Kuiper M, Verheule S, Schotten U (2018) Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria. Europace 20(1):140\u2013148","journal-title":"Europace"},{"key":"3891_CR70","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2020-0039","author":"LA Ritchie","year":"2020","unstructured":"Ritchie LA, Qin S, Penson PE, Henney NC, Lip GY (2020) Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. Future Cardiol. https:\/\/doi.org\/10.2217\/fca-2020-0039","journal-title":"Future Cardiol"},{"issue":"1","key":"3891_CR71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/FJC.0000000000000832","volume":"76","author":"W Ma","year":"2020","unstructured":"Ma W, Guo X, Wang Q, Sun G, Wang J (2020) Systematic review and meta-analysis appraising efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation. J Cardiovasc Pharmacol 76(1):32\u201341","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3891_CR72","doi-asserted-by":"crossref","first-page":"e12508","DOI":"10.1111\/anec.12508","volume":"23","author":"T Akel","year":"2018","unstructured":"Akel T, Lafferty J (2018) Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: a meta-analysis. Ann Noninvasive Electrocardiol 23(3):e12508","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"3","key":"3891_CR73","doi-asserted-by":"crossref","first-page":"e0213713","DOI":"10.1371\/journal.pone.0213713","volume":"14","author":"P Kanvatirth","year":"2019","unstructured":"Kanvatirth P, Jeeves RE, Bacon J, Besra GS, Alderwick LJ (2019) Utilisation of the prestwick chemical library to identify drugs that inhibit the growth of mycobacteria. PLoS ONE 14(3):e0213713","journal-title":"PLoS ONE"},{"issue":"3","key":"3891_CR74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1540-8167.2009.01623.x","volume":"21","author":"AE Acerda","year":"2010","unstructured":"Acerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM (2010) Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol 21(3):301\u2013310","journal-title":"J Cardiovasc Electrophysiol"},{"key":"3891_CR75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fncel.2018.00417","volume":"12","author":"C Zheng","year":"2018","unstructured":"Zheng C, Chen G, Tan Y, Zeng W, Peng Q, Wang J, Cheng C, Yang X, Nie S, Xu Y, Zhang Z, Papa SM, Ye K, Cao X (2018) TRH analog, taltirelin improves motor function of hemi-PD rats without inducing dyskinesia via sustained dopamine stimulating effect. Front Cell Neurosci 12:417","journal-title":"Front Cell Neurosci"},{"key":"3891_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.05.020","volume":"129","author":"KM Storey","year":"2020","unstructured":"Storey KM, Wang J, Garberich RF, Bennett NM, Traverse JH, Arndt TL, Schmidt CW, Henry TD (2020) Long-term (3 years) outcomes of ranolazine therapy for refractory angina pectoris (from the Ranolazine Refractory Registry). Am J Cardiol 129:1\u20134","journal-title":"Am J Cardiol"},{"issue":"4","key":"3891_CR77","first-page":"732","volume":"114","author":"VM Miranda","year":"2020","unstructured":"Miranda VM, Beserra SS, Campos DR (2020) Inotropic and antiarrhythmic transmural actions of ranolazine in a cellular model of type 3 long QT syndrome. Arq Bras Cardiol 114(4):732\u2013735","journal-title":"Arq Bras Cardiol"},{"issue":"13","key":"3891_CR78","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/bph.14223","volume":"175","author":"C Ferrantini","year":"2018","unstructured":"Ferrantini C, Pioner JM, Mazzoni L, Gentile F et al (2018) Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. Br J Pharmacol 175(13):2635\u20132652","journal-title":"Br J Pharmacol"},{"key":"3891_CR79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2019.05.008","volume":"132","author":"P Zhabyeyev","year":"2019","unstructured":"Zhabyeyev P, McLean B, Chen X, Vanhaesebroeck B, Oudit GY (2019) Inhibition of PI3Kinase-\u03b1 is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts. J Mol Cell Cardiol 132:98\u2013109","journal-title":"J Mol Cell Cardiol"},{"key":"3891_CR80","unstructured":"Reed M, Kerndt CC, Nicolas D (2020) Ranolazine. In: StatPearls, Treasure Island (FL): StatPearls Publishing; PMID: 29939605"},{"issue":"5","key":"3891_CR81","doi-asserted-by":"crossref","first-page":"e0216820","DOI":"10.1371\/journal.pone.0216820","volume":"14","author":"B Quintana-Villamandos","year":"2019","unstructured":"Quintana-Villamandos B, Gonz\u00e1lez MDC, Delgado-Martos MJ, Guti\u00e9rrez-Arzapalo PY, B\u00f6ger RH, L\u00fcneburg N, Mu\u00f1oz D, Delgado-Baeza E (2019) The protective effect of dronedarone on the structure and mechanical properties of the aorta in hypertensive rats by decreasing the concentration of symmetric dimethylarginine (SDMA). PLoS ONE 14(5):e0216820","journal-title":"PLoS ONE"},{"issue":"2","key":"3891_CR82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccep.2016.02.011","volume":"8","author":"M Shenasa","year":"2016","unstructured":"Shenasa M, Assadi H, Heidary S, Shenasa H (2016) Ranolazine: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias. Card Electrophysiol Clin 8(2):467\u2013479","journal-title":"Card Electrophysiol Clin"},{"issue":"12","key":"3891_CR83","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/14740338.2017.1387246","volume":"16","author":"MH Khan","year":"2017","unstructured":"Khan MH, Rochlani Y, Aronow WS (2017) Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation. Expert Opin Drug Saf 16(12):1407\u20131412","journal-title":"Expert Opin Drug Saf"},{"key":"3891_CR84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4137\/CMC.S6677","volume":"5","author":"GV Naccarelli","year":"2011","unstructured":"Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD (2011) Safety and efficacy of dronedarone in the treatment of atrial fibrillation\/flutter. Clin Med Insights Cardiol 5:103\u2013119","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"3891_CR85","doi-asserted-by":"crossref","first-page":"16562","DOI":"10.1038\/s41598-018-34348-0","volume":"8","author":"MJ Elliott","year":"2018","unstructured":"Elliott MJ, Jerzak KJ, Cockburn JG, Safikhani Z, Gwynne WD, Hassell JA, Bane A, Silvester J, Thu KL, Haibe-Kains B, Mak TW, Cescon DW (2018) The antiarrhythmic drug, dronedarone, demonstrates cytotoxic effects in breast cancer independent of thyroid hormone receptor alpha 1 (THR\u03b11) antagonism. Sci Rep 8(1):16562","journal-title":"Sci Rep"},{"issue":"6","key":"3891_CR86","first-page":"64","volume":"68","author":"SK Sonkar","year":"2020","unstructured":"Sonkar SK, Kumar A (2020) Coronary cameral fistula - a rare cause of angina pectoris in a young patient. J Assoc Phys India 68(6):64\u201365","journal-title":"J Assoc Phys India"},{"issue":"Suppl E","key":"3891_CR87","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1093\/eurheartj\/suaa075","volume":"22","author":"A Baggiano","year":"2020","unstructured":"Baggiano A, Guglielmo M, Muscogiuri G, Guaricci AI, Del Torto A, Pontone G (2020) (Epicardial and microvascular) angina or atypical chest pain: differential diagnoses with cardiovascular magnetic resonance. Eur Heart J Suppl 22(Suppl E):E116\u2013E120","journal-title":"Eur Heart J Suppl"},{"issue":"10","key":"3891_CR88","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/cvr\/cvz160","volume":"115","author":"BI Levy","year":"2019","unstructured":"Levy BI, Heusch G, Camici PG (2019) The many faces of myocardial ischaemia and angina. Cardiovasc Res 115(10):1460\u20131470","journal-title":"Cardiovasc Res"},{"key":"3891_CR89","unstructured":"Reed M, Kerndt CC, Nicolas D (2020) Ranolazine. 2020 May 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan\u2013. PMID: 29939605"},{"issue":"12","key":"3891_CR90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ejhf.678","volume":"18","author":"WA Heggermont","year":"2016","unstructured":"Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M (2016) Metabolic support for the heart: complementary therapy for heart failure? Eur J Heart Fail 18(12):1420\u20131429","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3891_CR91","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1074248418784290","volume":"24","author":"TF Schwemer","year":"2019","unstructured":"Schwemer TF, Radziwolek L, Deutscher N, Diermann N, Sehner S, Blankenberg S, Friedrich FW (2019) Effect of ranolazine on ischemic myocardium IN patients with acute cardiac ischemia (RIMINI-Trial): a randomized controlled pilot trial. J Cardiovasc Pharmacol Ther 24(1):62\u201369","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"3891_CR92","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1038\/s41598-018-22033-1","volume":"8","author":"M Abdelsayed","year":"2018","unstructured":"Abdelsayed M, Ruprai M, Ruben PC (2018) The efficacy of Ranolazine on E1784K is altered by temperature and calcium. Sci Rep 8(1):3643","journal-title":"Sci Rep"},{"issue":"10","key":"3891_CR93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18087\/cardio.2019.10.n601","volume":"59","author":"YN Belenkov","year":"2019","unstructured":"Belenkov YN, Ilgisonis IS, Naymann YI, Privalova EA, Zhito AV (2019) The use of selective inhibitor of If-channels ivabradine in patients with ischemic heart disease, heart failure with high heart rate. Kardiologiia 59(10):60\u201365","journal-title":"Kardiologiia"},{"issue":"2","key":"3891_CR94","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/eurheartj\/ehy504","volume":"40","author":"R Ferrari","year":"2019","unstructured":"Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, Manolis A, Marzilli M, Rosano GMC, Lopez-Sendon J, Fox K (2019) Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J 40(2):190\u2013194","journal-title":"Eur Heart J"},{"issue":"4","key":"3891_CR95","first-page":"e7868","volume":"12","author":"F Tahir","year":"2020","unstructured":"Tahir F, Bin Arif T, Majid Z, Ahmed J, Khalid M (2020) Ivabradine in postural orthostatic tachycardia syndrome: a review of the literature. Cureus 12(4):e7868","journal-title":"Cureus"},{"issue":"1","key":"3891_CR96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14740\/cr958","volume":"11","author":"TR Koroma","year":"2020","unstructured":"Koroma TR, Samura SK, Cheng Y, Tang M (2020) Effect of ivabradine on left ventricular diastolic function, exercise tolerance and quality of life in patients with heart failure: a systemic review and meta-analysis of randomized controlled trials. Cardiol Res 11(1):40\u201349","journal-title":"Cardiol Res"},{"issue":"3","key":"3891_CR97","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amjmed.2019.07.046","volume":"133","author":"TA Marciniak","year":"2020","unstructured":"Marciniak TA, Atar D, Serebruany V (2020) Does ivabradine decrease cardiovascular deaths in heart failure patients? Am J Med 133(3):347\u2013351","journal-title":"Am J Med"},{"issue":"5","key":"3891_CR98","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4103\/ijp.IJP_298_19","volume":"51","author":"LA Ahmed","year":"2019","unstructured":"Ahmed LA (2019) Nicorandil: a drug with ongoing benefits and different mechanisms in various diseased conditions. Indian J Pharmacol 51(5):296\u2013301","journal-title":"Indian J Pharmacol"},{"key":"3891_CR99","unstructured":"National Center for Biotechnology Information. PubChem Database (2020) Nicorandil, CID=47528, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Nicorandil. Accessed 6 July 2020"},{"issue":"2","key":"3891_CR100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jphs.2015.03.003","volume":"128","author":"M Marinko","year":"2015","unstructured":"Marinko M, Novakovic A, Nenezic D, Stojanovic I, Milojevic P, Jovic M, Ugresic N, Kanjuh V, Yang Q, He GW (2015) Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. J Pharmacol Sci 128(2):59\u201364","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"3891_CR101","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ccr3.830","volume":"5","author":"D Ooshiro","year":"2017","unstructured":"Ooshiro D, Yamaguchi S, Kakazu M, Arasaki O (2017) Effectiveness of continuous low-dose fasudil on refractory coronary vasospasm subsequent to cardiopulmonary arrest. Clin Case Rep 5(8):1207\u20131209","journal-title":"Clin Case Rep"},{"issue":"3","key":"3891_CR102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3233\/JPD-191909","volume":"10","author":"YJ Yang","year":"2020","unstructured":"Yang YJ, Bu LL, Shen C, Ge JJ, He SJ, Yu HL, Tang YL, Jue Z, Sun YM, Yu WB, Zuo CT, Wu JJ, Wang J, Liu FT (2020) Fasudil promotes \u03b1-synuclein clearance in an AAV-mediated \u03b1-synuclein rat model of Parkinson's disease by autophagy activation. J Parkinsons Dis 10(3):969\u2013979","journal-title":"J Parkinsons Dis"},{"issue":"13","key":"3891_CR103","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1523\/JNEUROSCI.0462-19.2020","volume":"40","author":"I Busti","year":"2020","unstructured":"Busti I, Allegra M, Spalletti C, Panzi C, Restani L, Billuart P, Caleo M (2020) ROCK\/PKA inhibition rescues hippocampal hyperexcitability and GABAergic neuron alterations in a oligophrenin-1 knock-out mouse model of X-linked intellectual disability. J Neurosci 40(13):2776\u20132788. https:\/\/doi.org\/10.1523\/JNEUROSCI.0462-19.2020","journal-title":"J Neurosci"},{"issue":"4","key":"3891_CR104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12012-019-09561-6","volume":"20","author":"Y Yan","year":"2020","unstructured":"Yan Y, Xiang C, Yang Z, Miao D, Zhang D (2020) Rho kinase inhibition by fasudil attenuates adriamycin-induced chronic heart injury. Cardiovasc Toxicol 20(4):351\u2013360","journal-title":"Cardiovasc Toxicol"},{"issue":"24","key":"3891_CR105","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.3390\/ijms20246361","volume":"20","author":"CR Panta","year":"2019","unstructured":"Panta CR, Ruisanchez \u00c9, M\u00f3r\u00e9 D, Dancs PT, Balogh A, F\u00fcl\u00f6p \u00c1, Ker\u00e9k M, Proia RL, Offermanns S, Tigyi GJ, Beny\u00f3 Z (2019) Sphingosine-1-phosphate enhances \u03b11-adrenergic vasoconstriction via S1P2-G12\/13-ROCK mediated signaling. Int J Mol Sci 20(24):6361","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3891_CR106","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2019.08.1056","volume":"74","author":"A Suda","year":"2019","unstructured":"Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Ikeda S, Sato K, Sugisawa J, Matsumoto Y, Miyata S, Sakata Y, Shimokawa H (2019) Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. J Am Coll Cardiol 74(19):2350\u20132360","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3891_CR107","doi-asserted-by":"crossref","first-page":"e12461","DOI":"10.1111\/1755-5922.12461","volume":"36","author":"R Yuan","year":"2018","unstructured":"Yuan R, Xin Q, Shi W, Liu W, Lee SM, Hoi P, Li L, Zhao J, Cong W, Chen K (2018) Vascular endothelial growth factor gene transfer therapy for coronary artery disease: a systematic review and meta-analysis. Cardiovasc Ther 36(5):e12461","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"3891_CR108","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1038\/s41598-019-48356-1","volume":"9","author":"H Sunaga","year":"2019","unstructured":"Sunaga H, Koitabashi N, Iso T, Matsui H, Obokata M, Kawakami R, Murakami M, Yokoyama T, Kurabayashi M (2019) Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: role of adrenergic overdrive and lipolysis byproducts. Sci Rep 9(1):11841","journal-title":"Sci Rep"},{"key":"3891_CR109","first-page":"6786302","volume":"2020","author":"A Huang","year":"2020","unstructured":"Huang A, Qi X, Cui Y, Wu Y, Zhou S, Zhang M (2020) Serum VEGF: diagnostic value of acute coronary syndrome from stable angina pectoris and prognostic value of coronary artery disease. Cardiol Res Pract 2020:6786302","journal-title":"Cardiol Res Pract"},{"key":"3891_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000812","author":"SM Chen","year":"2020","unstructured":"Chen SM, Li D, Xing X, Li ZP (2020) Higher serum angiopoietin 2 levels are independently associated with coronary microvascular dysfunction in patients with angina in the absence of obstructive coronary artery disease. Chin Med J (Engl). https:\/\/doi.org\/10.1097\/CM9.0000000000000812","journal-title":"Chin Med J (Engl)"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-020-03891-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:23:49Z","timestamp":1629933829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-020-03891-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1007\/s11010-020-03891-8","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The Author of this manuscript has no conflict of interest and responsible for all the writing content of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}